Top

Published in:

01-07-2012 | Special Feature

Improvement of survival and prospect of cure in patients with metastatic breast cancer

Authors: Yee Chung Cheng, Naoto T. Ueno

Published in: Breast Cancer | Issue 3/2012

Abstract

Patients with metastatic breast cancer have traditionally been considered incurable with conventional treatment. However, 5–10% of those patients survive more than 5 years, and 2–5% survive more than 10 years. Recent studies suggest that the survival of patients with metastatic breast cancer has been slowly improving. In this review, we examine the possible curative approach for a certain group of patients with metastatic breast cancer. We identify that patients most likely to benefit from such an aggressive approach are young and have good performance status, adequate body functional reserve, long disease-free interval before recurrence, oligometastatic disease, and low systemic tumor load. An aggressive multidisciplinary approach including both local treatment of macroscopic disease and systemic treatment of microscopic disease can result in prolonged disease control in certain patients with metastatic breast cancer. Whether patients with prolonged disease control are “cured” remains controversial.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRef

Falkson G, Gelman RS, Leone L, Falkson CI. Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer. 1990;66:1621–9.PubMedCrossRef

Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197–205.PubMed

Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100:44–52.PubMedCrossRef

Chia SK, Speers CH, D’Yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973–9.PubMedCrossRef

Haybittle JL. Curability of breast cancer. Br Med Bull. 1991;47:319–23.PubMed

Friedel G, Linder A, Toomes H. The significance of prognostic factors for the resection of pulmonary metastases of breast cancer. Thorac Cardiovasc Surg. 1994;42:71–5.PubMedCrossRef

Planchard D, Soria JC, Michiels S, Grunenwald D, Validire P, Caliandro R, et al. Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer. 2004;100:28–35.PubMedCrossRef

Staren ED, Salerno C, Rongione A, Witt TR, Faber LP. Pulmonary resection for metastatic breast cancer. Arch Surg. 1992;127:1282–4.PubMedCrossRef

10.

Lanza LA, Natarajan G, Roth JA, Putnam JB, Putnam JB Jr. Long-term survival after resection of pulmonary metastases from carcinoma of the breast. Ann Thorac Surg. 1992;54:244–7. (discussion 248).PubMedCrossRef

11.

McDonald ML, Deschamps C, Ilstrup DM, Allen MS, Trastek VF, Pairolero PC. Pulmonary resection for metastatic breast cancer. Ann Thorac Surg. 1994;58:1599–602.PubMedCrossRef

12.

Livartowski A, Chapelier A, Beuzedoc P, Dierick A, Asselain B, Dartevelle P, et al. Surgery of lung metastases of breast cancer: analysis of 40 cases. Bull Cancer. 1998;85:800.PubMed

13.

Murabito M, Salat A, Mueller MR. Complete resection of isolated lung metastasis from breast carcinoma results in a strong increase in survival. Minerva Chir. 2000;55:121–7.PubMed

14.

Friedel G, Pastorino U, Ginsberg RJ, Goldstraw P, Johnston M, Pass H, et al. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg. 2002;22:335–44.PubMedCrossRef

15.

Ludwig C, Stoelben E, Hasse J. Disease-free survival after resection of lung metastases in patients with breast cancer. Eur J Surg Oncol. 2003;29:532–5.PubMedCrossRef

16.

Tanaka F, Li M, Hanaoka N, Bando T, Fukuse T, Hasegawa S, et al. Surgery for pulmonary nodules in breast cancer patients. Ann Thorac Surg. 2005;79:1711–4. (discussion 1714–1715).PubMedCrossRef

17.

Rena O, Papalia E, Ruffini E, Filosso PL, Oliaro A, Maggi G, et al. The role of surgery in the management of solitary pulmonary nodule in breast cancer patients. Eur J Surg Oncol. 2007;33:546–50.PubMedCrossRef

18.

Yoshimoto M, Tada K, Nishimura S, Makita M, Iwase T, Kasumi F, et al. Favourable long-term results after surgical removal of lung metastases of breast cancer. Breast Cancer Res Treat. 2008;110:485–91.PubMedCrossRef

19.

Hoe AL, Royle GT, Taylor I. Breast liver metastases—incidence, diagnosis and outcome. J R Soc Med. 1991;84:714–6.PubMed

20.

Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol. 1987;5:773–82.PubMed

21.

Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T, Coleman R, et al. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline–taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer. 2003;39:2439–49.PubMedCrossRef

22.

Schneebaum S, Walker MJ, Young D, Farrar WB, Minton JP. The regional treatment of liver metastases from breast cancer. J Surg Oncol. 1994;55:26–31. (discussion 32).PubMedCrossRef

23.

Lorenz M, Wiesner J, Staib-Sebler E, Encke A. Regional therapy breast cancer liver metastases. Zentralbl Chir. 1995;120:786–90.PubMed

24.

Elias D, Lasser PH, Montrucolli D, Bonvallot S, Spielmann M. Hepatectomy for liver metastases from breast cancer. Eur J Surg Oncol. 1995;21:510–3.PubMedCrossRef

25.

Pocard M, Salmon RJ. Hepatic resection for breast cancer metastasis. The concept of adjuvant surgery. Bull Cancer. 1997;84:47–50.PubMed

26.

Raab R, Nussbaum KT, Behrend M, Weimann A. Liver metastases of breast cancer: results of liver resection. Anticancer Res. 1998;18:2231–3.PubMed

27.

Seifert JK, Weigel TF, Gonner U, Bottger TC, Junginger T. Liver resection for breast cancer metastases. Hepatogastroenterology. 1999;46:2935–40.PubMed

28.

Kondo S, Katoh H, Omi M, Hirano S, Ambo Y, Tanaka E, et al. Hepatectomy for metastases from breast cancer offers the survival benefit similar to that in hepatic metastases from colorectal cancer. Hepatogastroenterology. 2000;47:1501–3.PubMed

29.

Yoshimoto M, Tada T, Saito M, Takahashi K, Uchida Y, Kasumi F. Surgical treatment of hepatic metastases from breast cancer. Breast Cancer Res Treat. 2000;59:177–84.PubMedCrossRef

30.

Selzner M, Morse MA, Vredenburgh JJ, Meyers WC, Clavien PA. Liver metastases from breast cancer: long-term survival after curative resection. Surgery. 2000;127:383–9.PubMedCrossRef

31.

Maksan SM, Lehnert T, Bastert G, Herfarth C. Curative liver resection for metastatic breast cancer. Eur J Surg Oncol. 2000;26:209–12.PubMedCrossRef

32.

Pocard M, Pouillart P, Asselain B, Falcou MC, Salmon RJ. Hepatic resection for breast cancer metastases: results and prognosis (65 cases). Ann Chir. 2001;126:413–20.PubMedCrossRef

33.

Carlini M, Lonardo MT, Carboni F, Petric M, Vitucci C, Santoro R, et al. Liver metastases from breast cancer. Results of surgical resection. Hepatogastroenterology. 2002;49:1597–601.PubMed

34.

Singletary SE, Walsh G, Vauthey JN, Curley S, Sawaya R, Weber KL, et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist. 2003;8:241–51.PubMedCrossRef

35.

Elias D, Maisonnette F, Druet-Cabanac M, Ouellet JF, Guinebretiere JM, Spielmann M, et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg. 2003;185:158–64.PubMedCrossRef

36.

Arena E, Ferrero S. Surgical treatment of liver metastases from breast cancer. Minerva Chir. 2004;59:7–15.PubMed

37.

Vlastos G, Smith DL, Singletary SE, Mirza NQ, Tuttle TM, Popat RJ, et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol. 2004;11:869–74.PubMedCrossRef

38.

d’Annibale M, Piovanello P, Cerasoli V, Campioni N. Liver metastases from breast cancer: the role of surgical treatment. Hepatogastroenterology. 2005;52:1858–62.PubMed

39.

Ercolani G, Grazi GL, Ravaioli M, Ramacciato G, Cescon M, Varotti G, et al. The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol. 2005;12:459–66.PubMedCrossRef

40.

Okaro AC, Durkin DJ, Layer GT, Kissin MW, Karanjia ND. Hepatic resection for breast cancer metastases. Ann R Coll Surg Engl. 2005;87:167–70.PubMedCrossRef

41.

Sakamoto Y, Yamamoto J, Yoshimoto M, Kasumi F, Kosuge T, Kokudo N, et al. Hepatic resection for metastatic breast cancer: prognostic analysis of 34 patients. World J Surg. 2005;29:524–7.PubMedCrossRef

42.

Adam R, Aloia T, Krissat J, Bralet MP, Paule B, Giacchetti S, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244:897–907. (discussion 907–898).PubMedCrossRef

43.

Martinez SR, Young SE, Giuliano AE, Bilchik AJ. The utility of estrogen receptor, progesterone receptor, and Her-2/neu status to predict survival in patients undergoing hepatic resection for breast cancer metastases. Am J Surg. 2006;191:281–3.PubMedCrossRef

44.

Thelen A, Benckert C, Jonas S, Lopez-Hanninen E, Sehouli J, Neumann U, et al. Liver resection for metastases from breast cancer. J Surg Oncol. 2008;97:25–9.PubMedCrossRef

45.

Caralt M, Bilbao I, Cortes J, Escartin A, Lazaro JL, Dopazo C, et al. Hepatic resection for liver metastases as part of the “oncosurgical” treatment of metastatic breast cancer. Ann Surg Oncol. 2008;15:2804–10.PubMedCrossRef

46.

Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology. 2001;220:145–9.PubMed

47.

Lawes D, Chopada A, Gillams A, Lees W, Taylor I. Radiofrequency ablation (RFA) as a cytoreductive strategy for hepatic metastasis from breast cancer. Ann R Coll Surg Engl. 2006;88:639–42.PubMedCrossRef

48.

Gunabushanam G, Sharma S, Thulkar S, Srivastava DN, Rath GK, Julka PK, et al. Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. J Vasc Interv Radiol. 2007;18:67–72.PubMedCrossRef

49.

Sofocleous CT, Nascimento RG, Gonen M, Theodoulou M, Covey AM, Brody LA, et al. Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol. 2007;189:883–9.PubMedCrossRef

50.

Mack MG, Straub R, Eichler K, Sollner O, Lehnert T, Vogl TJ. Breast cancer metastases in liver: laser-induced interstitial thermotherapy—local tumor control rate and survival data. Radiology. 2004;233:400–9.PubMedCrossRef

51.

Fraschini G, Fleishman G, Yap HY, Carrasco CH, Charnsangavej C, Patt YZ, et al. Percutaneous hepatic arterial infusion of cisplatin for metastatic breast cancer. Cancer Treat Rep. 1987;71:313–5.PubMed

52.

Arai Y, Sone Y, Inaba Y, Ariyoshi Y, Kido C. Hepatic arterial infusion chemotherapy for liver metastases from breast cancer. Cancer Chemother Pharmacol. 1994;33(Suppl):S142–4.PubMedCrossRef

53.

Yayoi E, Furukawa J, Sekimoto M, Kinuta M, Tateishi H, Maruyama H, et al. A comparison of intra-arterial chemoembolization and infusion chemotherapy for liver metastases of breast cancer. Gan To Kagaku Ryoho. 1995;22:1519–22.PubMed

54.

Ikeda T, Adachi I, Takashima S, Ogita M, Aoyama H, Sano M, et al. A phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113. JCOG Breast Cancer Study Group. Jpn J Clin Oncol. 1999;29:23–7.PubMedCrossRef

55.

Gofuku J, Yayoi E, Ikeda N, Nishi T, Yagyu T, Kawasaki K. Long-term survivors with liver metastasis from breast cancer who were received intra-arterial chemotherapy. Gan To Kagaku Ryoho. 2004;31:1828–31.PubMed

56.

Giroux MF, Baum RA, Soulen MC. Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol. 2004;15:289–91.PubMedCrossRef

57.

Li XP, Meng ZQ, Guo WJ, Li J. Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol. 2005;11:3782–7.PubMed

58.

Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, et al. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer. 2007;109:2190–6.PubMedCrossRef

59.

Buijs M, Kamel IR, Vossen JA, Georgiades CS, Hong K, Geschwind JF. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol. 2007;18:957–63.PubMedCrossRef

60.

DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer. 1979;44:1913–8.PubMedCrossRef

61.

Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983;52:2349–54.PubMedCrossRef

62.

Boogerd W, Vos VW, Hart AA, Baris G. Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol. 1993;15:165–74.PubMedCrossRef

63.

Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007;110:2640–7.PubMedCrossRef

64.

Salvati M, Capoccia G, Orlando ER, Fiorenza F, Gagliardi FM. Single brain metastases from breast cancer: remarks on clinical pattern and treatment. Tumori. 1992;78:115–7.PubMed

65.

Wronski M, Arbit E, McCormick B. Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer. 1997;80:1746–54.PubMedCrossRef

66.

Boogerd W, Hart AA, Tjahja IS. Treatment and outcome of brain metastasis as first site of distant metastasis from breast cancer. J Neurooncol. 1997;35:161–7.PubMedCrossRef

67.

Pieper DR, Hess KR, Sawaya RE. Role of surgery in the treatment of brain metastases in patients with breast cancer. Ann Surg Oncol. 1997;4:481–90.PubMedCrossRef

68.

Firlik KS, Kondziolka D, Flickinger JC, Lunsford LD. Stereotactic radiosurgery for brain metastases from breast cancer. Ann Surg Oncol. 2000;7:333–8.PubMedCrossRef

69.

Amendola BE, Wolf AL, Coy SR, Amendola M, Bloch L. Gamma knife radiosurgery in the treatment of patients with single and multiple brain metastases from carcinoma of the breast. Cancer J. 2000;6:88–92.PubMed

70.

Lederman G, Wronski M, Fine M. Fractionated radiosurgery for brain metastases in 43 patients with breast carcinoma. Breast Cancer Res Treat. 2001;65:145–54.PubMedCrossRef

71.

Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J. Treatment of cerebral metastases from breast cancer with stereotactic radiosurgery. Strahlenther Onkol. 2004;180:590–6.PubMedCrossRef

72.

Goyal S, Prasad D, Harrell F Jr, Matsumoto J, Rich T, Steiner L. Gamma knife surgery for the treatment of intracranial metastases from breast cancer. J Neurosurg. 2005;103:218–23.PubMedCrossRef

73.

Akyurek S, Chang EL, Mahajan A, Hassenbusch SJ, Allen PK, Mathews LA, et al. Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer. Am J Clin Oncol. 2007;30:310–4.PubMedCrossRef

74.

Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med. 1986;81:381–6.PubMedCrossRef

75.

Briasoulis E, Karavasilis V, Kostadima L, Ignatiadis M, Fountzilas G, Pavlidis N. Metastatic breast carcinoma confined to bone: portrait of a clinical entity. Cancer. 2004;101:1524–8.PubMedCrossRef

76.

Boxer DI, Todd CE, Coleman R, Fogelman I. Bone secondaries in breast cancer: the solitary metastasis. J Nucl Med. 1989;30:1318–20.PubMed

77.

Noguchi S, Miyauchi K, Nishizawa Y, Imaoka S, Koyama H, Iwanaga T. Results of surgical treatment for sternal metastasis of breast cancer. Cancer. 1988;62:1397–401.PubMedCrossRef

78.

Incarbone M, Nava M, Lequaglie C, Ravasi G, Pastorino U. Sternal resection for primary or secondary tumors. J Thorac Cardiovasc Surg. 1997;114:93–9.PubMedCrossRef

79.

Lequaglie C, Massone PB, Giudice G, Conti B. Gold standard for sternectomies and plastic reconstructions after resections for primary or secondary sternal neoplasms. Ann Surg Oncol. 2002;9:472–9.PubMedCrossRef

80.

Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002;132:620–6. (discussion 626–627).PubMedCrossRef

81.

Babiera GV, Rao R, Feng L, Meric-Bernstam F, Kuerer HM, Singletary SE, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol. 2006;13:776–82.PubMedCrossRef

82.

Khan SA. Does resection of an intact breast primary improve survival in metastatic breast cancer? Oncology (Williston Park). 2007;21:924–31. (discussion 931–922, 934, 942, passim).

83.

Wood WC. Breast surgery in advanced breast cancer: local control in the presence of metastases. Breast. 2007;16(Suppl 2):S63–6.PubMedCrossRef

84.

Fields RC, Jeffe DB, Trinkaus K, Zhang Q, Arthur C, Aft R, et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol. 2007;14:3345–51.PubMedCrossRef

85.

Leung AM, Vu HN, Nguyen KA, Thacker LR, Bear HD. Effects of surgical excision on survival of patients with stage IV breast cancer. J Surg Res. 2010;161:83–8.PubMedCrossRef

86.

Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother. 2005;54:1137–42.PubMedCrossRef

87.

Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER data. Ann Surg Oncol. 2007;14:2187–94.PubMedCrossRef

88.

Carmichael AR, Anderson ED, Chetty U, Dixon JM. Does local surgery have a role in the management of stage IV breast cancer? Eur J Surg Oncol. 2003;29:17–9.PubMedCrossRef

89.

Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24:2743–9.PubMedCrossRef

90.

Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008;247:732–8.PubMedCrossRef

91.

Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J. 2002;8:2–9.PubMedCrossRef

92.

Stadtmauer EA, O’Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med. 2000;342:1069–76.PubMedCrossRef

93.

Stadtmauer EA, O’Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (SCT) for metastatic breast cancer: 5-year update of the ‘Philadelphia Trial’ (PBT-01). Proc Am Soc Clin Oncol. 2002;21 (abstract 169).

94.

Crown J, Perey L, Lind M, Guillem V, Efremedis A, Garcia-Conde J, et al. Superiority of tandem high-dose chemotherapy (HDC) versus optimized conventionally-dosed chemotherapy (CDC) in patients (pts) with metastatic breast cancer (MBC): the International Breast Cancer Dose Intensity Study (IBDIS 1). Proc Am Soc Clin Oncol. 2003;22 (abstract 88).

95.

Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol. 2005;23:432–40.PubMedCrossRef

96.

Lotz JP, Cure H, Janvier M, Asselain B, Morvan F, Legros M, et al. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer. 2005;41:71–80.PubMedCrossRef

97.

Vredenburgh JJ, Coniglio D, Broadwater G, Jones RB, Ross M, Shpall EJ, et al. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transpl. 2006;12:195–203.CrossRef

98.

Vredenburgh JJ, Madan B, Coniglio D, Ross M, Broadwater G, Niedzwiecki D, et al. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transpl. 2006;37:1009–15.CrossRef

99.

Biron P, Durand M, Roche H, Delozier T, Battista C, Fargeot P, et al. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transpl. 2008;41:555–62.CrossRef

100.

Crump M, Gluck S, Tu D, Stewart D, Levine M, Kirkbride P, et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol. 2008;26:37–43.PubMedCrossRef

101.

Berry D, Ueno NT, Johnson MM, Lei X, Smith DA, Caputo J, et al. High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 6 randomized metastatic breast cancer trials. Cancer Res. 2009;69(Suppl):392s. (abstract 6113).

102.

Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin Oncol. 2002;20:620–3.PubMed

Title: Improvement of survival and prospect of cure in patients with metastatic breast cancer
Authors: Yee Chung Cheng
Naoto T. Ueno
Publication date: 01-07-2012
Publisher: Springer Japan
Published in: Breast Cancer / Issue 3/2012
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-011-0276-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

From improved survival to potential cure in patients with metastatic breast cancer

Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer

Three cases of kindred with familial breast cancer in which carrier detection by BRCA gene testing was performed on family members

Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review

High safety profile and activity of oral vinorelbine in an elderly patient with metastatic breast cancer

Background enhancement of mammary glandular tissue on breast dynamic MRI: imaging features and effect on assessment of breast cancer extent

Keynote webinar | Spotlight on antibody–drug conjugates in cancer